Yahoo Finance • 2 days ago
Delcath Systems, Inc. (NASDAQ:DCTH) is one of the best medical device stocks to buy according to analysts. On August 6, H.C. Wainwright analyst Swayampakula Ramakanth maintained a bullish stance on Delcath Systems, Inc. (NASDAQ:DCTH), givi... Full story
Yahoo Finance • 9 days ago
Earnings Call Insights: Delcath Systems (DCTH) Q2 2025 MANAGEMENT VIEW * Gerard J. Michel, CEO, highlighted, "Quarterly revenue reached $24.2 million, an increase of over 20% compared to the first quarter of 2025, reflecting continued... Full story
Yahoo Finance • 9 days ago
* Delcath Systems press release [https://seekingalpha.com/pr/20190883-delcath-systems-reports-second-quarter-2025-results-and-business-highlights] (NASDAQ:DCTH [https://seekingalpha.com/symbol/DCTH]): Q2 GAAP EPS of $0.07 beats by $0.05.... Full story
Yahoo Finance • 5 months ago
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent me... Full story
Yahoo Finance • 3 years ago
NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financia... Full story
Yahoo Finance • 3 years ago
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate in the Canaccord Genuity Hori... Full story
Yahoo Finance • 3 years ago
NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will be participating... Full story
Yahoo Finance • 3 years ago
NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financi... Full story